Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma

• Published in: BMC cancer 2016-01, Vol.16 (9), p.9-9, Article 9
• Main Authors: Vandewynckel, Yves-Paul, Laukens, Debby, Devisscher, Lindsey, Bogaerts, Eliene, Paridaens, Annelies, Van den Bussche, Anja, Raevens, Sarah, Verhelst, Xavier, Van Steenkiste, Christophe, Jonckx, Bart, Libbrecht, Louis, Geerts, Anja, Carmeliet, Peter, Van Vlierberghe, Hans
• Format: Article
• Language: English
• Subjects: Animals; Carcinoma, Hepatocellular - chemically induced; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - pathology; Care and treatment; Cell Hypoxia - drug effects; Cell Hypoxia - genetics; Complications and side effects; Development and progression; Diagnosis; Diethylnitrosamine - toxicity; Disease Models, Animal; eIF-2 Kinase - biosynthesis; eIF-2 Kinase - genetics; Endoplasmic Reticulum Stress - genetics; Gene Expression Regulation, Neoplastic - drug effects; Glycosaminoglycans - physiology; Hep G2 Cells; Hepatoma; Humans; Liver Neoplasms - chemically induced; Liver Neoplasms - genetics; Liver Neoplasms - pathology; Mice; Mice, Knockout; Neovascularization, Pathologic - genetics; Neovascularization, Pathologic - pathology; Placenta Growth Factor; Pregnancy Proteins - biosynthesis; Pregnancy Proteins - genetics; Tumor Microenvironment - genetics; Tyrosine metabolism; Unfolded Protein Response - genetics
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-015-1990-6

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. We previously showed that the inhibition of placental growth factor (PlGF) exerts antitumour effects and induces vessel normalisation, possibly reducing hypoxia. However, the exact mechanism underlying these effects remains unclear. Because hypoxia and endoplasmic reticulum stress, which activates the unfolded protein response (UPR), have been implicated in HCC progression, we assessed the interactions between PlGF and these microenvironmental stresses. PlGF knockout mice and validated monoclonal anti-PlGF antibodies were used in a diethylnitrosamine-induced mouse model for HCC. We examined the interactions among hypoxia, UPR activation and PlGF induction in HCC cells. Both the genetic and pharmacological inhibitions of PlGF reduced the chaperone levels and the activation of the PKR-like endoplasmic reticulum kinase (PERK) pathway of the UPR in diethylnitrosamine-induced HCC. Furthermore, we identified that tumour hypoxia was attenuated, as shown by reduced pimonidazole binding. Interestingly, hypoxic exposure markedly activated the PERK pathway in HCC cells in vitro, suggesting that PlGF inhibition may diminish PERK activation by improving oxygen delivery. We also found that PlGF expression is upregulated by different chemical UPR inducers via activation of the inositol-requiring enzyme 1 pathway in HCC cells. PlGF inhibition attenuates PERK activation, likely by tempering hypoxia in HCC via vessel normalisation. The UPR, in turn, is able to regulate PlGF expression, suggesting the existence of a feedback mechanism for hypoxia-mediated UPR that promotes the expression of the angiogenic factor PlGF. These findings have important implications for our understanding of the effect of therapies normalising tumour vasculature.